Methods of Treating Retinal Vasculopathies
OwnerRemi-Martin Laberge, Scott Kimura +5inventors
InventorsRemi-Martin Laberge, Scott Kimura, Przemyslaw Sapieha, Pamela Tsuruda, Pieter Bas-Kwak, Nathan Gushwa, Tianna Chow
Life of this patent
Estimating the term…
Abstract
The invention relates to methods of treating certain retinal vasculopathies such as diabetic macular edema, diabetic retinopathy and dry and neovascular age-related macular degeneration, among others. In some instances, the method includes treating a patient suffering from a retinal vasculopathy by administering an agent to the patient. The agent can be one or more of the agents as described herein.
Claims22
A method of inhibiting pathogenic neovascularization in a diseased eye comprising administering an agent, wherein the agent is selected from the group consisting of an inhibitor of GPX4, an inhibitor of GLS1, an inhibitor of PAPP-A, an inhibitor of cGAS, an inhibitor of STING, an inhibitor of mTOR, or an agonist of GCN2.
A method of inhibiting vascular leak in a diseased eye comprising administering an agent, wherein the agent is selected from the group consisting of an inhibitor of GPX4, an inhibitor of GLS1, an inhibitor of PAPP-A, an inhibitor of cGAS, an inhibitor of STING, an inhibitor of mTOR, or an agonist of GCN2.
A method of eliminating senescent endothelial cells comprising contacting the cells with an inhibitor of GPX4, an inhibitor of GLS1, an inhibitor of PAPP-A, an inhibitor of cGAS, an inhibitor of STING, an inhibitor of mTOR, or an agonist of GCN2.
A method of eliminating senescent pericytes comprising contacting the cells with an inhibitor of GPX4, an inhibitor of GLS1, an inhibitor of PAPP-A, an inhibitor of cGAS, an inhibitor of STING, an inhibitor of mTOR, or an agonist of GCN2.
A method of treating a patient suffering from a retinal vasculopathy comprising administering an agent to the patient, wherein the agent is selected from the group consisting of an inhibitor of GPX4, an inhibitor of GLS1, an inhibitor of PAPP-A, an inhibitor of cGAS, an inhibitor of STING, an inhibitor of mTOR, or an agonist of GCN2.
Dependencies are inferred from the claim text.